๐ŸŽ Black Friday: up to 50% off of annual plans
Lisata Therapeutics, Inc. (LSTA)
NASDAQ: LSTA ยท Real-Time Price ยท USD
0.8989
-0.0111 (-1.22%)
At close: Nov 20, 2026, 4:00 PM EST
0.8800
-0.0189 (-2.10%)
After-hours: Nov 20, 2026, 7:45 PM EST
โ† View all transcripts

Jefferies Global Healthcare Conference

Nov 17, 2026

Summary

MAR001 showed substantial triglyceride reductions without a glucose signal in phase IIb; confirmatory sHTG data and MAR005 dose selection are expected in 2027. MAR002 phase II data are also expected in 2027, ahead of planned phase III initiation in H1 2028.

Operator

All right. So good morning, everyone, and welcome to the Jefferies 2026 Global Healthcare Conference. It is my pleasure to introduce you now Josh Lehrer, CEO of Marea Therapeutics. Just a reminder that the presentation will be 20 minutes long, follow up with a five minutes Q&A. Thank you.

Josh Lehrer
CEO, Marea Therapeutics

Thanks, and thanks to the Jefferies team for having us here. Can you guys see slides? Okay, great. I'll be making forward-looking statements today. Marea recently completed a merger with Lisata Therapeutics with a concurrent PIPE financing that has financed us through middle of 2028 and through a number of important milestones for our programs. Marea, we are focused on developing two clinical stage molecules. Both are founded on strong human genetics and have the potential to transform the treatment of diseases for important indications where existing therapies can deliver efficacy, but both come with limitations, and we think we can improve on patient outcomes. Our lead program is MAR001. This is a first-in-class antibody to ANGPTL4, and MAR005, its half-life extended variant, which will become our phase III molecule. And we're developing this program to treat patients suffering from severe hypertriglyceridemia.

sHTG affects three million individuals in the U.S., and these patients are really at dual risk from both cardiovascular disease as well as acute pancreatitis, which is a devastating clinical outcome. ApoC-III inhibitors, of which one is now approved, have demonstrated that potent lowering of triglycerides can drastically reduce these adverse outcomes and reduce pancreatitis events. This efficacy does come at a cost, and that cost is worse glucose control, which is a significant issue because the majority of these patients have type 2 diabetes, many poorly controlled. Our phase IIb data, which we recently presented, and I'll go over here, demonstrates a profile that's different. It's very encouraging in indicating that we may have a molecule that can match the ApoC-III inhibitors on efficacy, on triglyceride lowering, ultimately pancreatitis event reduction, but have a clean metabolic profile on glucose.

We think that's important in a large number of patients and a commercial opportunity that's projected to grow to $10 billion or more in the U.S. Our second program is MAR002. This is the first long-acting direct growth hormone antagonist that's being developed for acromegaly. Acromegaly is a severe endocrine disease with significant morbidity and mortality in patients who are untreated and not treated to goal, to achieve full biochemical control and normalization of growth hormone levels as assessed by IGF-1. Most patients remain uncontrolled despite first-line therapy with somatostatin receptor ligands. We know that the most effective class of drugs in this disease is direct growth hormone blockade, but there's only one available therapy in this class, and it has significant limitations, including daily dosing and safety tolerability issues for patients.

We've designed what we think can become an optimal direct growth hormone antagonist with a significantly improved profile in terms of dosing and safety and tolerability. We have healthy volunteer phase I data that goes a long way towards establishing this profile. I'll review that data today. We think that this can really transform the treatment and become the mainstay of therapy for most patients, getting most patients to goal. This is projected to grow to become a large U.S. opportunity. It's a $1.4 billion total in acromegaly, but we think that an optimal direct growth hormone antagonist alone could be in excess of that opportunity. Where the programs stand now, leading towards a number of milestones in 2027. For our lead program in sHTG, we have read out a phase IIb study, and that's the data I'll be reviewing today.

We are now screening patients in a second part to that study, which will add additional numbers of patients who have severe hypertriglyceridemia. That dataset will be available by the end of next year. For our phase III candidate, MAR005, this is an improved half-life extended variant of MAR001. This is currently in an ongoing PK/PD bridging study for which we have FDA agreement, and the next step for that study is dose selection data, which we'll be disclosing around the middle of next year, and then moving towards phase III start before the end of next year. For MAR002, we've completed, as I mentioned, a healthy volunteer phase I study, and even though this is a phase I study, the data is very informative on the profile of the molecule with proof of mechanism data. We'll review that today.

We started dosing patients in a phase II proof of concept study in September, and that study will read out with interim data in the middle of the year, complete data by the end of the year, and then we plan to move quickly towards phase III initiation in the first half of 2028. First, sHTG, and this is the need. There are three million total patients in the United States. About a million of these patients are at significant risk of pancreatitis events, many with recurrent pancreatitis. The main thing to know here is that these episodes carry really significant morbidity and mortality, really on the level of myocardial infarction. The difference being that until very recently, there were no therapies that had ever demonstrated clinical benefit for these patients in reducing these events and these adverse outcomes.

The other point is that these patients are really being co-managed by their cardiologist, endocrinologist, and lipidologist, not just for the pancreatitis risk, but also in most cases for diagnosed type 2 diabetes, in many cases difficult to control diabetes, and also established coronary disease, as well as fatty liver. Aside from the patient impact, this is an expensive disease to take care of with standard of care therapies that were really inadequate. ApoC-III inhibitors, a new class of therapies, one is now approved, the other from Arrowhead has phase III data, and this really stands to transform treatment of this disease by delivering a step change in efficacy. By dramatically lowering triglyceride over what standard of care is able to achieve, most patients can be brought down below the risk threshold.

Pancreatitis events were really significantly cut down, and we don't see hazard ratios like 0.15 very often in clinical trials these days, but we have with these drugs. That's what's driving projections of really significant opportunity, commercial opportunity, as well as patient impact. But this efficacy does come at a cost. What's seen here is the very consistent lowering of triglycerides across the two most advanced ApoC-III inhibitors, delivering triglyceride reductions in the range of 60%-80% in terms of change from baseline. But what's also consistent is a worsening in glucose control, and that's seen across trials in diabetic patients, an increase of approximately 0.3 points in hemoglobin A1C. That's seen consistently. This has consequence in some patients. We know that in the experience with plozasiran, dysglycemia was the leading cause of adverse events, and in the open-label extension, also the leading cause of treatment discontinuations.

Why do we think that our target and our molecule can be different? We target a different protein, ANGPTL4, compared to ApoC-III, and really the main difference is where these two different proteins act and where the triglycerides are being disposed of. With ANGPTL4, this protein is a very potent inhibitor of triglyceride metabolism in adipose tissue. It shuts down lipoprotein lipase in adipose tissue. MAR001, by inhibiting ANGPTL4, is leading to triglyceride disposal in the adipose tissue, really putting fat back where it belongs, and there's no metabolic penalty to that. In contrast, ApoC-III has a number of different functions, but predominantly leads to uptake of triglyceride-rich lipoproteins in the liver and disposal of triglycerides in the liver. That's thought to lead to these metabolic signals, really as an on-mechanism effect, by having the potential to lead to deposition of ectopic fat in the liver.

One of the ApoC-III inhibitors has a clear liver fat signal. Also to substrate switching, so preference in the liver for utilizing fatty acids over glucose and a risk of hyperglycemia. The human genetics actually predict this as well, so that's another difference. People who are missing this gene for ANGPTL4 actually have benefits in terms of reduced risk of diabetes and better insulin sensitivity. With ApoC-III, it's actually just the opposite, and that predicts the risk that's seen with the pharmacology and with the molecules that have been tested in the clinic. We designed a study to test whether MAR001 can actually deliver on a different profile. The study we designed is the TYDAL-TIMI 78 study, phase IIb study. We tested MAR001 in 235 patients across three active arms and placebo, dosed monthly.

We treated patients for 24 weeks, and about half of these patients were diabetic, so very much informative on the metabolic profile. We looked at a wide range of triglyceride levels from 150 up to 880, so a subset of these patients had severe elevations in triglycerides and were sHTG patients. What we saw was a dose-dependent lowering of triglycerides through 12 weeks maintained to 24 weeks. At the high dose, we saw about 40% decrease in triglycerides from baseline. This was presented at AHA, and there's a QR code here for New England Journal publication for this data as well. What was really new was what we learned when we looked at subgroups, and when we looked at the effect of MAR001 in patients with more severe triglyceride elevations, and that's what's shown here.

This is data from the middle and high dose that were pooled and compared to placebo, and what we saw was a scaled efficacy increasing from about 40% - 50% in patients with triglycerides over 300, and then to over 70% in patients with triglycerides over 500. This was the subgroup that had severe elevations. These are the patients we will be treating going forward. The caveat is that this was a subgroup. This study was not designed as a pure sHTG study, but what was very encouraging is when we looked at individual patient data, which is shown on the right, we saw that the effects were remarkably consistent. Every patient in the middle and high dose group achieved between a 60%- 80% reduction in triglycerides.

When we look at that really side to side compared to the ApoC-III inhibitors, what we see is in these severe patients, triglyceride lowering that is very much comparable, and we know that triglyceride lowering accurately predicts subsequent reduction in pancreatitis events. So, potential to deliver the same kind of transformative efficacy that has been seen with ApoC-III inhibitors for these patients, but the glucose is different. You can see that in contrast to the 0.3 point increase in diabetic patients, that is seen really across the board, and that is despite active medical management in these trials with anti-diabetic therapies. We see no hint of a signal on glucose, actually a numeric reduction compared to placebo, and we have also seen no hint of any liver signals or liver fat with this molecule as well.

The emerging profile really looks encouraging in terms of being able to deliver potential improvements, especially to patients with comorbid diabetes. Next question is this important? Why does this matter? I think the first point to make is that this glucose increase is not going to stand in the way of use of ApoC-III inhibitors. Pancreatitis is a severe outcome, and that risk is bigger than managing through worsened glucose in diabetics. However, when we presented physicians with a profile, equal in efficacy without the metabolic penalty, in patients where diabetes is at a high prevalence, including poorly controlled diabetes, that is really where we saw a lot of excitement and a preference. What we heard is that, all things being equal, for new starts, the most important attribute in weighing treatment decisions would be stability of glucose levels.

As we heard from an endocrinologist, new starts would go to the cleaner profile. This is important in addressing a large portion of these patients. 1.8 million of the three million patients in the U.S. have type 2 diabetes, and about half of these patients are already poorly controlled. Avoiding that metabolic penalty offers the potential to improve glucose control, not need to move patients onto insulin or escalate insulin doses, and these are in patients where, in many cases, physicians were already struggling to maintain their glucose control and their other cardiovascular risk factors. Really, the outstanding question for this program is confirming the data that we have already seen in bigger numbers with patients with severe hypertriglyceridemia, and that is what we are doing now.

We're screening patients in an extension to our phase II-B, part B of the study, and this study will randomize about 100 patients one-to-one. One active dose we chose from the initial part of the phase II-B, compared to placebo, treated for 24 weeks. We expect at least half of the patients to have type 2 diabetes, and we'll be evaluating really the same types of endpoints we looked at in the first part of the study. The goal will be confirming really four things.

One is strong triglyceride reductions comparable to the ApoC-III class, getting the majority of patients down below the risk threshold of 500, and we know that that predicts reduction, dramatic reductions in pancreatitis events, continuing to see neutral metabolic signal, lack of glucose increase, and then continuing to see what has been to date a very clean safety profile without any drug-related safety signals identified to date. Moving on to acromegaly, there are some similarities here. We have a molecule that we think can improve the trade-offs to patients over a molecule that already is known to deliver strong efficacy. Acromegaly is a disease affecting about 30,000 patients in the U.S.

It's an endocrine disorder caused by a pituitary adenoma that secretes excess growth hormone, and the problem with that is that excess growth hormone leads to lots of downstream tissue damage, early morbidity, highly symptomatic, and early mortality when not successfully treated. First line is surgical treatment, but the majority of patients require lifelong medical therapy with the goal of normalizing growth hormone levels, and that's really assessed by the downstream biomarker of IGF-1. The goal is normalizing IGF-1 levels, and there are two ways to do this. The first are drugs in the somatostatin receptor ligand class. Some may be familiar with the most recent approval in this class, paltusotine, a drug developed by Crinetics and then acquired by Vertex. These drugs aim to decrease the secretion of growth hormone by cells in the tumor.

The other class is direct growth hormone antagonists, which act peripherally to block growth hormone signaling at the level of the receptor, and there's only one available agent in that class, which is called pegvisomant. This contrasts the two classes of drugs. While somatostatin receptor ligands are often used first line in patients after surgery, the major challenge is that the response rates are low. This is data taken straight from the paltusotine label, which shows that less than one in four patients actually achieves full biochemical control. These are naive patients who had not been treated before. Really, the unmet need and the group of patients who are undertreated is nearly 80%. In contrast, pegvisomant has delivered in clinical trials really outstanding efficacy, bringing the majority of patients, over 80%, to full biochemical control and delivering effectiveness, improvement in symptoms as well.

Might ask the question why pegvisomant is not the mainstay of therapy, which it is not, and that's due to really significant limitations in the profile of this drug. Pegvisomant is a significant burden for patients. It requires daily injection. It's powder in a vial. Patients have to reconstitute this themselves at home. It's also a pegylated peptide that leads to, in many cases, severe injection site reactions and LFT elevations that require monitoring. A difficult drug to take. In the real world, effectiveness is much lower than in clinical trials. When we've talked to patients, we often hear that the best they've ever felt is on pegvisomant, a direct growth hormone blocker, but patients simply can't keep up with the daily dosing, given the burden as well as the tolerability profile.

We've designed what we think can become an optimal direct growth hormone antagonist for that 80% of patients who are not at goal. We designed a long-acting antibody that blocks the receptor. The goal is delivering much better dosing. Our goal is dosing once every two weeks compared to daily, a presentation in an autoinjector to make this easy for patients, with a clean safety profile, avoiding injection site reactions and LFT elevations that have been seen with pegvisomant, and delivering really on the promise of this class with real-world use. This could be transformative for patients. This could also be a significant commercial opportunity. As I mentioned before, the total projections for medical therapy in acromegaly are in the $1.4 billion range.

We think that an optimal direct growth hormone antagonist alone, though, could be in that range, really due to addressing significant number of patients who are unaddressed currently. Phase I actually told us a lot about whether we can achieve this profile, and that's because we can actually look at the pharmacodynamic endpoint, look at proof of mechanism in healthy volunteers, and benchmark this molecule to prior drugs in this disease. This shows data from our phase I study, IGF-1 levels over time after single ascending doses, and in the dark line is the highest single dose that we tested, and then multiple doses, three doses of that same dose given every two weeks.

What we were hoping to see is IGF-1 suppression really on par with what had been seen with pegvisomant in prior phase I healthy volunteer studies, and that bar is shown in the red line. About 50% IGF-1 suppression we know translates very well into patients in phase II and phase III into efficacy, and we saw with a single dose that we achieved approximately 50% reduction, so we were encouraged with that data. With multiple doses, actually exceeded 50% IGF-1 suppression. 65% IGF-1 suppression is actually the biggest drop that's been seen with any agent in this class or any class. The other important test in this trial was really the durability of the response, and that's where we see a very striking difference with pegvisomant.

Compared to a few days of IGF-1 suppression with pegvisomant after a single dose, we saw this as staying for six weeks with our antibody, and the safety and tolerability profile have been also very encouraging. No drug-related safety signals identified, and importantly, no LFT elevations or injection site reactions. This early data stacks up very well, makes us very encouraged that we have a best-in-class profile here that could become best in disease in terms of efficacy in acromegaly. It demonstrates really due to an allosteric mechanism that can't be outcompeted by growth hormone levels, in contrast to pegvisomant, where we see greater in vitro potency. We've seen similar, if not greater, effects in the clinic now in healthy volunteers in IGF-1 suppression, about 10 times greater durability, and the PK in our phase I study supports dosing every two weeks in the majority of patients.

Possible that we could go less frequent in some patients, and no safety signals identified. Next step is to confirm this in patients. We know that healthy volunteers is predictive, but now the job is to really prove this in patients. We're now dosing in a phase II proof-of-concept study, 72 patients, three active arms compared to placebo. IGF-1 levels change rapidly, so our endpoint here is a 10-week IGF-1 endpoint, and we'll be looking to confirm what we've seen in phase I. Seeing IGF-1 suppression, again, on par with pegvisomant in the same range. PK in patients now that supports dosing at a significant benefit. The goal is weekly or better. We think that we'll end up at every two weeks, and then continuing to deliver on a safety profile that will be an improvement over current therapies, and currently really is very well tolerated.

As we move into 2027, we have a lot of data coming. First, in the MAR001 program, we'll have data on our phase III molecule, so this is identical to MAR001. We've just engineered Fc variants to extend the half-life and decrease the clearance and improve the dosing profile. Data from that PK/PD bridging study on dose selection for phase III will be available in the middle of 2027. We'll have additional data on greater number of patients with sHTG to confirm the profile we've seen to date by the end of next year and then plan to initiate phase III. For MAR002, we'll have data from our phase II proof-of-concept study that we're calling TROUGH-2. Interim data middle of the year, complete data by the end of the year, and then we'll be initiating phase III in the beginning of 2028.

As we move into next year, we'll really be answering the two most important questions for these programs. On MAR001, it's really confirming the profile we've seen in greater numbers of sHTG and this profile that could become best of disease. For our second program, it's confirming the profile we've seen in phase I that also could lead to a best-in-class and best of disease profile, and we're funded through all these milestones. Thank you.